Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?
Some Chinese companies are allowed to make cheap versions of Merck’s molnupiravir based on the MPP agreement.We analyzed the impact and outlook,...
332 Views
Zai Lab Ltd (ZLAB.US) - The Strength and the Concerns
This insight analyzes Zai Lab about its distinctive pipeline, the management team, the concerns on license-in mode, regulatory...
389 Views
Alphamab Co Ltd (9966.HK) - Some Points Worth the Attention
The article analyzed Alphamab Oncology in terms of its conservativeness on business operation and decision making in early stages, the concerns on...
329 Views
Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?
The article mainly analyzed Junshi in terms of the pipeline, commercialization strategy, the talents, the outlook, the related concerns, as well as...
405 Views
MicroPort MedBot Pre-IPO - Thoughts on Valuation
MicroPort MedBot (MM), a surgical robot company, aims to raise up to US$1bn in its Hong Kong IPO. It is a subsidiary of Microport Scientific (853...
492 Views